Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. affiliate David Gee filed to sell ordinary shares, par value NIS 0.00001, of Cellebrite DI Ltd. on Nasdaq. The planned sale covers 653 shares through Morgan Stanley Smith Barney LLC, connected to restricted share units that vested under an S-8 registered compensation plan.
Over the prior three months, David Gee reported sales of 228 shares, 2,243 shares, and 3,430 shares of the same class of ordinary shares, each with corresponding aggregate dollar values listed.
Cellebrite DI Ltd. insider Marcus Jewell has indicated an intent to sell up to 1,045 ordinary shares of the company’s stock through Morgan Stanley Smith Barney LLC. These shares relate to restricted share units that vested on August 11, 2026 under an S-8 registered compensation plan.
In the prior three months, Jewell reported selling 383 ordinary shares on May 12, 2026 for $4,982.83 and 12,658 ordinary shares on May 18, 2026 for $161,656.58.
Cellebrite DI Ltd. Chief Financial Officer David Barter reported an open-market sale of 41,734 ordinary shares at a weighted average price of $16.3756 per share. The filing states the shares were originally granted as RSUs on July 7, 2025 and that the disposition is associated with tax obligations related to their vesting.
After the transaction, Barter directly holds 334,219 ordinary shares. The price reflects multiple trades between $16.21 and $16.62 per share.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan reported an open-market sale of 103,188 ordinary shares. The shares were originally granted as restricted stock units on September 19, 2025, and the disposition is associated with tax obligations arising from the RSU vesting.
The shares were sold at a weighted average price of $15.7566 per share, in multiple trades between $15.44 and $15.97. Following this transaction, Hogan directly holds 590,777 ordinary shares of Cellebrite DI Ltd.
Company reported Form 144 notice showing proposed sales of common stock by an individual related party. The excerpt lists restricted stock vesting of 29,330 shares on 02/14/2024, and two reported dispositions in the past three months: 126,264 shares on 06/01/2026 and 43,983 shares on 07/01/2026.
Cellebrite DI Ltd. submitted a Rule 144 notice relating to Ordinary shares, par value NIS 0.00001, tied to vested Restricted Share Units under an issuer S-8 registered plan.
The filing lists 93,989 shares and references broker Morgan Stanley Smith Barney LLC; transaction dates shown include 07/07/2026 and 07/08/2026.
CLBT reports proposed sales of Common Stock under Form 144 by an affiliate and recent past disposals. The filing lists planned sales of 24,435 shares and 19,548 shares described as "Exercise of Options Under a Registered Plan" and shows 126,264 shares sold during the prior three months. Monetary figures appear in the excerpt as $677,342.60 and $2,000,968.74.
Cellebrite DI Ltd. filed a Rule 144 notice to sell 282,905 ordinary shares. The shares are described as Restricted Share Units vested under an issuer S-8 registered plan and the filing lists Morgan Stanley Smith Barney LLC as the broker. The filing shows dates 07/01/2026 and 07/02/2026.
CLBT submitted a Form 144 reporting a proposed sale of 126,264 shares of Common Stock with an aggregate value of $2,000,968.74, to be sold through Morgan Stanley Smith Barney LLC on 06/01/2026 on NASDAQ. The filing also lists two related option-exercise quantities of 60,606 and 65,658 shares dated 06/01/2026.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported net open-market sales of 5,673 ordinary shares of Cellebrite (CLBT). The sales occurred on May 21, 2026 at weighted average prices of about $13.15 and $13.10 per share, within disclosed ranges of $13.00–$13.30 and $12.98–$13.32.
According to the footnotes, the shares sold were originally granted as restricted stock units on May 20, 2024, and the dispositions are associated with his tax obligations upon vesting. After these transactions, Gee directly holds 142,032 ordinary shares of Cellebrite. The filing states that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Gee on November 18, 2025, indicating they were scheduled in advance.